Cook R&D Goals Suggest Logic Behind $219 Mil. Deal With Baxter
This article was originally published in The Gray Sheet
Executive Summary
Cook Group's divestiture of its Pharmaceutical Solutions unit to Baxter Healthcare for $219 mil. in cash and stock will help the privately-held firm focus on U.S. clinical trial enrollment for its Logic PTX paclitaxel-coated stent for anti-restenosis